Ardelyx, Inc. Stock Plummets to New 52-Week Low of $3.87

Ardelyx, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.87 on August 13, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 39.47%, contrasting sharply with the S&P 500's gain of 20.6% during the same period. The company's financial metrics reveal a challenging landscape. Ardelyx has reported a pre-tax profit of USD -37.6 million, reflecting a dramatic decline of 148.04%. Similarly, net profit figures have also fallen by 144.19%, indicating ongoing difficulties in achieving profitability. The stock's price-to-book ratio stands at 8.05, suggesting that the market is valuing the company at a premium relative to its book value. Additionally, Ardelyx's return on equity is notably negative at -36.90%, and the company carries a debt-to-equity ratio of -0.36. With a market capitalization of USD 1,344 million and no dividend yield, Ardelyx continues to navigate a challenging financial environment as it seeks to stabilize its operations and performance.